Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BM
The experimentally established mechanism targets of Amantadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 3/20 | 0.68 |
| ▸ | GRIN3B known ✓ | O60391 | 3/20 | 0.68 |
| ▸ | GRIN1 known ✓ | Q05586 | 3/20 | 0.68 |
| ▸ | GRIN2A known ✓ | Q12879 | 3/20 | 0.68 |
| ▸ | GRIN2B known ✓ | Q13224 | 3/20 | 0.68 |
| ▸ | GRIN2C known ✓ | Q14957 | 3/20 | 0.68 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.68 |
| ▸ | STAT6 | P42226 | 1/20 | 0.68 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.68 |
| ▸ | THRB | P10828 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amantadine SCHEMBL5919747 | 1.00 | LMNA (0.68) | LMNAGRIN2DGRIN3BGRIN1GRIN2A | |
| Amantadine SCHEMBL1073029 | 1.00 | LMNA (0.68) | LMNAGRIN2DGRIN3BGRIN1GRIN2A | |
| Amantadine SCHEMBL29011286 | 0.83 | GRIN1 (0.87) | LMNAGRIN2DGRIN3BGRIN1GRIN2A | |
| Amantadine SCHEMBL21309814 | 0.83 | GRIN1 (1.00) | LMNAGRIN2DGRIN3BGRIN1GRIN2A | |
| Amantadine SCHEMBL15532073 | 0.83 | GRIN1 (1.00) | LMNAGRIN2DGRIN3BGRIN1GRIN2A | |
| Amantadine SCHEMBL3642447 | 0.83 | GRIN1 (1.00) | LMNAGRIN2DGRIN3BGRIN1GRIN2A | |
| Amantadine SCHEMBL4098 | 0.83 | GRIN1 (1.00) | LMNAGRIN2DGRIN3BGRIN1GRIN2A | |
| Amantadine SCHEMBL21310017 | 0.83 | GRIN1 (1.00) | LMNAGRIN2DGRIN3BGRIN1GRIN2A | |
| Amantadine SCHEMBL15672299 | 0.83 | GRIN1 (1.00) | LMNAGRIN2DGRIN3BGRIN1GRIN2A | |
| Amantadine SCHEMBL20409394 | 0.83 | GRIN1 (1.00) | LMNAGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119661366-A | Preparation method and application of amantadine carbonate | 李果 | 2025-03-21 | — | — | CN | claimed |
| CN-117843492-A | Method for separating and extracting product in production of amantadine | 四川众邦新材料股份有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-112010764-A | Preparation method of 3-hydroxy-1-amantadine transition state intermediate | 江苏泰洁智邦检测技术有限公司 | 2020-12-01 | — | — | CN | claimed |
| CN-107325010-A | The safe preparation method and device of a kind of adamantanol | 四川众邦制药有限公司 | 2017-11-07 | — | — | CN | claimed |
| CN-102883601-A | amantadine compositions and methods of use thereof | ADAMAS PHARMACEUTICALS INC | 2013-01-16 | — | — | CN | claimed |
| EP-2506709-A2 | AMANTADINE COMPOSITIONS AND METHODS OF USE | Adamas Pharmaceuticals, Inc. (US) | 2012-10-10 | — | — | EP | claimed |
| WO-2011069010-A2 | AMANTADINE COMPOSITIONS AND METHODS OF USE | ADAMAS PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | claimed |
| EP-1562860-B1 | METHOD FOR PRODUCING ALKALINE EARTH SULPHATE NANOPARTICLES | CT FUER ANGEWANDTE NANOTECHNOLOGIE CAN GMBH (DE) | 2011-04-27 | — | — | EP | claimed |
| US-7288239-B2 | Having a crystal lattice of Mg, Ca, Sr and/or Ba sulfate obtained by controlled crystal growth in a non-aqueous solvent such as glycerin, ethylene glycol, polyethylene glycols, polyalcohols or dimethyl sulfoxide with coordinating properties | NANOSOLUTIONS GMBH (DE) | 2007-10-30 | — | — | US | claimed |
| US-20060133987-A1 | Having a crystal lattice of Mg, Ca, Sr and/or Ba sulfate obtained by controlled crystal growth in a non-aqueous solvent such as glycerin, ethylene glycol, polyethylene glycols, polyalcohols or dimethyl sulfoxide with coordinating properties | CENTRUM FUR ANGEWANDTE NANOTECHNOLOGIE (CAN) GMBH (DE) | 2006-06-22 | — | — | US | claimed |
| EP-0935461-B1 | ADAMANTANE AMINE DERIVATIVES FOR THE TREATMENT OF VIRUSES OF THE BORNAVIRIDAE FAMILY | LUDWIG HANNS (DE) | 2003-07-30 | — | — | EP | claimed |
| US-6384083-B1 | CONTROLLING VIRUSES OF BORNAVIRIDAE FAMILY BY ADMINISTERING ADAMANTANE AMINES TO HUMAN AND ANIMALS AT THERAPEUTICALLY EFFECTIVE DOSAGE BY MEANS SELECTED FROM ORAL, PARENTERAL, INTRAMUSCULAR, SUBCUTANEOUS, INTRADERMAL AND TOPICAL | Ludwig, Hanns (DE) | 2002-05-07 | — | — | US | claimed |
| CN-1235540-A | Use of amantadine or structurally similar compounds for combating borna disease virus and preventing and treating affective disorders and other diseases associated with BDV infection in humans and animals | LUDWIG H (DE) | 1999-11-17 | — | — | CN | claimed |
| EP-4719353-A1 | REVERSIBLE SURFACTANT AND MULTIFUNCTIONAL DRUG DELIVERY SYSTEMS BASED THEREON | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-04-08 | — | — | EP | disclosed |
| US-20260091073-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4620534-A2 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | CyDex Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | disclosed |
| EP-0139504-B1 | ADAMANTYLAMINE/LONG CHAIN ALKYLAMINE CATALYSTS AND USE IN PARAFFIN-OLEFIN ALKYLATION PROCESS | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1988-06-08 | — | — | EP | disclosed |
| US-4560825-A | CHARGE TRANSFER, LEWIS ACIDS, ADAMANTANYLAMINE AND DODECYLAMINE; ANTIKNOCK COMPOUNDS | EXXON RESEARCH & ENGINEERING COMPANY (US) | 1985-12-24 | — | — | US | disclosed |
| EP-0139504-A1 | Adamantylamine/long chain alkylamine catalysts and use in paraffin-olefin alkylation process | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1985-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091073-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | GYS2, COL1A1, COL14A1 | GRIN2D 4810/4885GRIN3B 4720/4885GRIN1 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.